Bile acid and inflammation activate gastric cardia stem cells in a mouse model of barrett-like metaplasia

Cancer Cell

Volumn 21, Issue 1, 2012, Pages 36-51

  Quante, Michael ^a,d   Bhagat, Govind ^a   Abrams, Julian A ^a   Marache, Frederic ^a   Good, Pamela ^a   Lee, Michele D ^a   Lee, Yoomi ^a   Friedman, Richard ^a   Asfaha, Samuel ^a   Dubeykovskaya, Zinaida ^a   Mahmood, Umar ^b   Figueiredo, Jose Luiz ^b   Kitajewski, Jan ^a   Shawber, Carrie ^a   Lightdale, Charles J ^a   Rustgi, Anil K ^c   Wang, Timothy C ^a  

^a New York Presbyterian Morgan Stanley Children's Hospital   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BILE ACID; BONE MORPHOGENETIC PROTEIN 4; INTERLEUKIN 1BETA; INTERLEUKIN 6; NITROSAMINE; NOTCH1 RECEPTOR; TRANSCRIPTION FACTOR CDX2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BARRETT ESOPHAGUS; CELL ACTIVATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGITIS; HISTOPATHOLOGY; MOUSE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; STEM CELL; STOMACH CARDIA STEM CELL; UPREGULATION;

MUS MUSCULUS;

EID: 84862909168     PISSN: 15356108     EISSN: 18783686     Source Type: Journal    
DOI: 10.1016/j.ccr.2011.12.004     Document Type: Article

References (68)

1. Allison P.R., Johnstone A.S. The oesophagus lined with gastric mucous membrane. Thorax 1953, 8:87-101.
2. Barbera M., Fitzgerald R.C. Cellular origin of Barrett metaplasia and oesophageal stem cells. Biochem. Soc. Trans. 2010, 38:370-373.
3. Barker N., Huch M., Kujala P., van de Wetering M., Snippert H.J., van Es J.H., Sato T., Stange D.E., Begthel H., van den Born M., et al. Lgr5(+ve) stem cells drive self-renewal in the stomach and build long-lived gastric units invitro. Cell Stem Cell 2010, 6:25-36.
4. Benedito R., Roca C., Sörensen I., Adams S., Gossler A., Fruttiger M., Adams R.H. The notch ligands Dll4 and Jagged1 have opposing effects on angiogenesis. Cell 2009, 137:1124-1135.
5. Bernstein H., Payne C.M., Bernstein C., Schneider J., Beard S.E., Crowley C.L. Activation of the promoters of genes associated with DNA damage, oxidative stress, ER stress and protein malfolding by the bile salt, deoxycholate. Toxicol. Lett. 1999, 108:37-46.
6. Bernstein H., Bernstein C., Payne C.M., Dvorakova K., Garewal H. Bile acids as carcinogens in human gastrointestinal cancers. Mutat. Res. 2005, 589:47-65.
7. Björkdahl O., Akerblad P., Gjörloff-Wingren A., Leanderson T., Dohlsten M. Lymphoid hyperplasia in transgenic mice over-expressing a secreted form of the human interleukin-1beta gene product. Immunology 1999, 96:128-137.
8. Bollrath J., Phesse T.J., von Burstin V.A., Putoczki T., Bennecke M., Bateman T., Nebelsiek T., Lundgren-May T., Canli O., Schwitalla S., et al. gp130-mediated Stat3 activation in enterocytes regulates cell survival and cell-cycle progression during colitis-associated tumorigenesis. Cancer Cell 2009, 15:91-102.
9. Brembeck F.H., Moffett J., Wang T.C., Rustgi A.K. The keratin 19 promoter is potent for cell-specific targeting of genes in transgenic mice. Gastroenterology 2001, 120:1720-1728.
10. Chatelain D., Fléjou J.F. High-grade dysplasia and superficial adenocarcinoma in Barrett esophagus: histological mapping and expression of p53, p21 and Bcl-2 oncoproteins. Virchows Arch. 2003, 442:18-24.
11. Corley D.A., Kubo A., Levin T.R., Block G., Habel L., Rumore G., Quesenberry C., Buffler P. Race, ethnicity, sex and temporal differences in Barrett oesophagus diagnosis: a large community-based study, 1994-2006. Gut 2009, 58:182-188.
12. Dvorak K., Payne C.M., Chavarria M., Ramsey L., Dvorakova B., Bernstein H., Holubec H., Sampliner R.E., Guy N., Condon A., et al. Bile acids in combination with low pH induce oxidative stress and oxidative DNA damage: relevance to the pathogenesis of Barrett oesophagus. Gut 2007, 56:763-771.
13. Ernst M., Najdovska M., Grail D., Lundgren-May T., Buchert M., Tye H., Matthews V.B., Armes J., Bhathal P.S., Hughes N.R., et al. STAT3 and STAT1 mediate IL-11-dependent and inflammation-associated gastric tumorigenesis in gp130 receptor mutant mice. J.Clin. Invest. 2008, 118:1727-1738.
14. Falk G.W. Barrett esophagus. Gastroenterology 2002, 122:1569-1591.
15. Fein M., Peters J.H., Chandrasoma P., Ireland A.P., Oberg S., Ritter M.P., Bremner C.G., Hagen J.A., DeMeester T.R. Duodenoesophageal reflux induces esophageal adenocarcinoma without exogenous carcinogen. J.Gastrointest. Surg. 1998, 2:260-268.
16. Fitzgerald R.C., Abdalla S., Onwuegbusi B.A., Sirieix P., Saeed I.T., Burnham W.R., Farthing M.J. Inflammatory gradient in Barrett oesophagus: implications for disease complications. Gut 2002, 51:316-322.
17. Fox J.G., Beck P., Dangler C.A., Whary M.T., Wang T.C., Shi H.N., Nagler-Anderson C. Concurrent enteric helminth infection modulates inflammation and gastric immune responses and reduces Helicobacter-induced gastric atrophy. Nat. Med. 2000, 6:536-542.
18. Fridlender Z.G., Sun J., Kim S., Kapoor V., Cheng G., Ling L., Worthen G.S., Albelda S.M. Polarization of tumor-associated neutrophil phenotype by TGF-beta: " N1" versus " N2" TAN. Cancer Cell 2009, 16:183-194.
19. Gatenby P.A., Ramus J.R., Caygill C.P., Shepherd N.A., Watson A. Relevance of the detection of intestinal metaplasia in non-dysplastic columnar-lined oesophagus. Scand. J. Gastroenterol. 2008, 43:524-530.
20. Giannakis M., Stappenbeck T.S., Mills J.C., Leip D.G., Lovett M., Clifton S.W., Ippolito J.E., Glasscock J.I., Arumugam M., Brent M.R., Gordon J.I. Molecular properties of adult mouse gastric and intestinal epithelial progenitors in their niches. J.Biol. Chem. 2006, 281:11292-11300.
21. Goldblum J.R. Controversies in the diagnosis of Barrett esophagus and Barrett-related dysplasia: one pathologist's perspective. Arch. Pathol. Lab. Med. 2010, 134:1479-1484.
22. Gough M.D., Ackroyd R., Majeed A.W., Bird N.C. Prediction of malignant potential in reflux disease: are cytokine polymorphisms important?. Am. J. Gastroenterol. 2005, 100:1012-1018.
23. Grivennikov S., Karin M. Autocrine IL-6 signaling: a key event in tumorigenesis?. Cancer Cell 2008, 13:7-9.
24. Grivennikov S.I., Greten F.R., Karin M. Immunity, inflammation, and cancer. Cell 2010, 140:883-899.
25. Hamilton S.R., Yardley J.H. Regenerative of cardiac type mucosa and acquisition of Barrett mucosa after esophagogastrostomy. Gastroenterology 1977, 72:669-675.
26. Hanby A.M., Jankowski J.A., Elia G., Poulsom R., Wright N.A. Expression of the trefoil peptides pS2 and human spasmolytic polypeptide (hSP) in Barrett metaplasia and the native oesophageal epithelium: delineation of epithelial phenotype. J.Pathol. 1994, 173:213-219.
27. Howlett M., Giraud A.S., Lescesen H., Jackson C.B., Kalantzis A., Van Driel I.R., Robb L., Van der Hoek M., Ernst M., Minamoto T., et al. The interleukin-6 family cytokine interleukin-11 regulates homeostatic epithelial cell turnover and promotes gastric tumor development. Gastroenterology 2009, 136:967-977.
28. Hvid-Jensen F., Pedersen L., Drewes A.M., Sørensen H.T., Funch-Jensen P. Incidence of adenocarcinoma among patients with Barrett esophagus. N.Engl. J. Med. 2011, 365:1375-1383.
29. Jankowski J.A., Wright N.A., Meltzer S.J., Triadafilopoulos G., Geboes K., Casson A.G., Kerr D., Young L.S. Molecular evolution of the metaplasia-dysplasia-adenocarcinoma sequence in the esophagus. Am. J. Pathol. 1999, 154:965-973.
30. Jankowski J.A., Harrison R.F., Perry I., Balkwill F., Tselepis C. Barrett metaplasia. Lancet 2000, 356:2079-2085.
31. Jiang L., Gonda T.A., Gamble M.V., Salas M., Seshan V., Tu S., Twaddell W.S., Hegyi P., Lazar G., Steele I., et al. Global hypomethylation of genomic DNA in cancer-associated myofibroblasts. Cancer Res. 2008, 68:9900-9908.
32. Jin G., Ramanathan V., Quante M., Baik G.H., Yang X., Wang S.S., Tu S., Gordon S.A., Pritchard D.M., Varro A., et al. Inactivating cholecystokinin-2 receptor inhibits progastrin-dependent colonic crypt fission, proliferation, and colorectal cancer in mice. J.Clin. Invest. 2009, 119:2691-2701.
33. Kalabis J., Oyama K., Okawa T., Nakagawa H., Michaylira C.Z., Stairs D.B., Figueiredo J.L., Mahmood U., Diehl J.A., Herlyn M., Rustgi A.K. A subpopulation of mouse esophageal basal cells has properties of stem cells with the capacity for self-renewal and lineage specification. J.Clin. Invest. 2008, 118:3860-3869.
34. Kauer W.K., Peters J.H., DeMeester T.R., Feussner H., Ireland A.P., Stein H.J., Siewert R.J. Composition and concentration of bile acid reflux into the esophagus of patients with gastroesophageal reflux disease. Surgery 1997, 122:874-881.
35. Kazumori H., Ishihara S., Rumi M.A., Kadowaki Y., Kinoshita Y. Bile acids directly augment caudal related homeobox gene Cdx2 expression in oesophageal keratinocytes in Barrett epithelium. Gut 2006, 55:16-25.
36. Kelty C.J., Gough M.D., Van Wyk Q., Stephenson T.J., Ackroyd R. Barrett oesophagus: intestinal metaplasia is not essential for cancer risk. Scand. J. Gastroenterol. 2007, 42:1271-1274.
37. Kim T.H., Shivdasani R.A. Notch signaling in stomach epithelial stem cell homeostasis. J.Exp. Med. 2011, 208:677-688.
38. Leedham S.J., Preston S.L., McDonald S.A., Elia G., Bhandari P., Poller D., Harrison R., Novelli M.R., Jankowski J.A., Wright N.A. Individual crypt genetic heterogeneity and the origin of metaplastic glandular epithelium in human Barrett oesophagus. Gut 2008, 57:1041-1048.
39. Lesina M., Kurkowski M.U., Ludes K., Rose-John S., Treiber M., Kloppel G., Yoshimura A., Reindl W., Sipos B., Akira S., et al. Stat3/Socs3 activation by IL-6 transsignaling promotes progression of pancreatic intraepithelial neoplasia and development of pancreatic cancer. Cancer Cell 2011, 19:456-469.
40. Li Y., Martin R.C. Reflux injury of esophageal mucosa: experimental studies in animal models of esophagitis, Barrett's esophagus and esophageal adenocarcinoma. Dis. Esophagus 2007, 20:372-378.
41. Means A.L., Xu Y., Zhao A., Ray K.C., Gu G. A CK19(CreERT) knockin mouse line allows for conditional DNA recombination in epithelial cells in multiple endodermal organs. Genesis 2008, 46:318-323.
42. Menke V., van Es J.H., de Lau W., van den Born M., Kuipers E.J., Siersema P.D., de Bruin R.W., Kusters J.G., Clevers H. Conversion of metaplastic Barrett epithelium into post-mitotic goblet cells by gamma-secretase inhibition. Dis. Model Mech. 2010, 3:104-110.
43. Nakagawa H., Wang T.C., Zukerberg L., Odze R., Togawa K., May G.H., Wilson J., Rustgi A.K. The targeting of the cyclin D1 oncogene by an Epstein-Barr virus promoter in transgenic mice causes dysplasia in the tongue, esophagus and forestomach. Oncogene 1997, 14:1185-1190.
44. Nakanishi Y., Saka M., Eguchi T., Sekine S., Taniguchi H., Shimoda T. Distribution and significance of the oesophageal and gastric cardiac mucosae: a study of 131 operation specimens. Histopathology 2007, 51:515-519.
45. O'Riordan J.M., Abdel-Latif M.M., Ravi N., McNamara D., Byrne P.J., McDonald G.S., Keeling P.W., Kelleher D., Reynolds J.V. Proinflammatory cytokine and nuclear factor kappa-B expression along the inflammation-metaplasia-dysplasia-adenocarcinoma sequence in the esophagus. Am. J. Gastroenterol. 2005, 100:1257-1264.
46. Odze R.D., Maley C.C. Neoplasia without dysplasia: lessons from Barrett esophagus and other tubal gut neoplasms. Arch. Pathol. Lab. Med. 2010, 134:896-906.
47. Ogiya K., Kawano T., Ito E., Nakajima Y., Kawada K., Nishikage T., Nagai K. Lower esophageal palisade vessels and the definition of Barrett esophagus. Dis. Esophagus 2008, 21:645-649.
48. Payne C.M., Crowley-Weber C.L., Dvorak K., Bernstein C., Bernstein H., Holubec H., Crowley C., Garewal H. Mitochondrial perturbation attenuates bile acid-induced cytotoxicity. Cell Biol. Toxicol. 2005, 21:215-231.
49. Playford R.J. New British Society of Gastroenterology (BSG) guidelines for the diagnosis and management of Barrett oesophagus. Gut 2006, 55:442.
50. Quante M., Marrache F., Goldenring J.R., Wang T.C. TFF2 mRNA transcript expression marks a gland progenitor cell of the gastric oxyntic mucosa. Gastroenterology 2010, 139:2018-2027.
51. Riddell R.H., Odze R.D. Definition of Barrett esophagus: time for a rethink-is intestinal metaplasia dead?. Am. J. Gastroenterol. 2009, 104:2588-2594.
52. Sato F., Meltzer S.J. CpG island hypermethylation in progression of esophageal and gastric cancer. Cancer 2006, 106:483-493.
53. Spechler S.J., Fitzgerald R.C., Prasad G.A., Wang K.K. History, molecular mechanisms, and endoscopic treatment of Barrett esophagus. Gastroenterology 2010, 138:854-869.
54. Stairs D.B., Nakagawa H., Klein-Szanto A., Mitchell S.D., Silberg D.G., Tobias J.W., Lynch J.P., Rustgi A.K. Cdx1 and c-Myc foster the initiation of transdifferentiation of the normal esophageal squamous epithelium toward Barrett esophagus. PLoS ONE 2008, 3:e3534.
55. Stairs D.B., Bayne L.J., Rhoades B., Vega M.E., Waldron T.J., Kalabis J., Klein-Szanto A., Lee J.S., Katz J.P., Diehl J.A., et al. Deletion of p120-catenin results in a tumor microenvironment with inflammation and cancer that establishes it as a tumor suppressor gene. Cancer Cell 2011, 19:470-483.
56. Takubo K., Aida J., Naomoto Y., Sawabe M., Arai T., Shiraishi H., Matsuura M., Ell C., May A., Pech O., et al. Cardiac rather than intestinal-type background in endoscopic resection specimens of minute Barrett adenocarcinoma. Hum. Pathol. 2009, 40:65-74.
57. Tatsuta T., Mukaisho K., Sugihara H., Miwa K., Tani T., Hattori T. Expression of Cdx2 in early GRCL of Barrett esophagus induced in rats by duodenal reflux. Dig. Dis. Sci. 2005, 50:425-431.
58. Theisen J., Nehra D., Citron D., Johansson J., Hagen J.A., Crookes P.F., DeMeester S.R., Bremner C.G., DeMeester T.R., Peters J.H. Suppression of gastric acid secretion in patients with gastroesophageal reflux disease results in gastric bacterial overgrowth and deconjugation of bile acids. J.Gastrointest. Surg. 2000, 4:50-54.
59. Tomita H., Takaishi S., Menheniott T.R., Yang X., Shibata W., Jin G., Betz K.S., Kawakami K., Minamoto T., Tomasetto C., et al. Inhibition of gastric carcinogenesis by the hormone gastrin is mediated by suppression of TFF1 epigenetic silencing. Gastroenterology 2011, 104:879-891.
60. Tu S., Bhagat G., Cui G., Takaishi S., Kurt-Jones E.A., Rickman B., Betz K.S., Penz-Oesterreicher M., Bjorkdahl O., Fox J.G., Wang T.C. Overexpression of interleukin-1beta induces gastric inflammation and cancer and mobilizes myeloid-derived suppressor cells in mice. Cancer Cell 2008, 14:408-419.
61. Vaccaro B.J., Gonzalez S., Poneros J.M., Stevens P.D., Capiak K.M., Lightdale C.J., Abrams J.A. Detection of intestinal metaplasia after successful eradication of Barrett Esophagus with radiofrequency ablation. Dig. Dis. Sci. 2011, 56:1996-2000.
62. Van De Bovenkamp J.H., Korteland-Van Male A.M., Warson C., Büller H.A., Einerhand A.W., Ectors N.L., Dekker J. Gastric-type mucin and TFF-peptide expression in Barrett oesophagus is disturbed during increased expression of MUC2. Histopathology 2003, 42:555-565.
63. Wang X., Ouyang H., Yamamoto Y., Kumar P.A., Wei T.S., Dagher R., Vincent M., Lu X., Bellizzi A.M., Ho K.Y., et al. Residual embryonic cells as precursors of a Barrett-like metaplasia. Cell 2011, 145:1023-1035.
64. Warson C., Van De Bovenkamp J.H., Korteland-Van Male A.M., Büller H.A., Einerhand A.W., Ectors N.L., Dekker J. Barrett esophagus is characterized by expression of gastric-type mucins (MUC5AC, MUC6) andTFF peptides (TFF1 and TFF2), but the risk of carcinoma development may be indicated by the intestinal-type mucin, MUC2. Hum. Pathol. 2002, 33:660-668.
65. Watanabe F., Iwasaki Y., Ohashi M., Nunobe S., Iwagami S., Takahashi K., Yamaguchi T., Matsumoto H., Yasutome M. [A case report-the marked response to S-1+ CDDP chemotherapy for post-operative local recurrence of advanced gastric cancer]. Gan To Kagaku Ryoho 2007, 34:1970-1972.
66. Winter J.W., Paterson S., Scobie G., Wirz A., Preston T., McColl K.E. N-nitrosamine generation from ingested nitrate via nitric oxide in subjects with and without gastroesophageal reflux. Gastroenterology 2007, 133:164-174.
67. Yang X.D., Ai W., Asfaha S., Bhagat G., Friedman R.A., Jin G., Park H., Shykind B., Diacovo T.G., Falus A., Wang T.C. Histamine deficiency promotes inflammation-associated carcinogenesis through reduced myeloid maturation and accumulation of CD11b+Ly6G+ immature myeloid cells. Nat. Med. 2011, 17:87-95.
68. Yu W.Y., Slack J.M., Tosh D. Conversion of columnar to stratified squamous epithelium in the developing mouse oesophagus. Dev. Biol. 2005, 284:157-170.